Bilcare Limited (BI) fundamentals
Bilcare Limited is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as BI (ISIN INE986A01012). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Bilcare Limited does
Bilcare Limited is an India-based company. The Company is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, and Research and Development (R&D) services. It has a single operating segment, namely Pharma Packaging Research Solutions. The Company offers a range of Pharma Packaging solutions, namely Blister Films, Blister Foils, Lidding Foils, Child-resistant (CR) Foils, and Laminations. Its R&D services include Formulation stability studies, Blister / Foil design & development, Pharma brand innovation, Analytical research & market study, and Packaging trials & audit. The Company has five subsidiaries, namely Bilcare GCS Limited, Bilcare Inc., Bilcare GCS Inc., Bilcare GCS Ireland Limited, Bilcare Pharma Solutions Limited, and Caprihans India Limited. Its annual manufacturing capacity is approximately 50000 tons. The Company has manufacturing facilities in Nashik, Pune, and Thane.
Valuation and market data
| Last close | ₹92.92 |
|---|---|
| Market capitalisation | ₹427 crore |
| Enterprise value | ₹901 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.72 |
| Price to sales (TTM) | 0.53 |
| Book value per share | ₹128.39 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Mon Apr 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹26 crore | ₹2 crore | ₹1 crore | 0.00 |
| Mar 2025 | ₹33 crore | ₹5 crore | ₹4 crore | 1.70 |
| Mar 2024 | ₹26 crore | ₹6 crore | ₹5 crore | 2.27 |
| Mar 2023 | ₹18 crore | ₹503 crore | ₹391 crore | 165.97 |
| Mar 2022 | ₹445 crore | ₹-24 crore | ₹-18 crore | -7.55 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 30.0% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 69.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.